Skip to main content

Table 2 Summary of safety and tolerability over 2 years

From: Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

Event, n (%)

Eptinezumab 300 mg N = 128

Any TEAE

91 (71.1)

Any study drug-related TEAE

18 (14.1)

Any severe TEAE

13 (10.2)

Any serious TEAE

5 (3.9)

Any TEAE leading to study drug withdrawal

8 (6.3)

Any TEAE leading to study drug interruption

10 (7.8)

Any TEAE resulting in death

0

  1. TEAE Treatment-emergent adverse event